- Home
- ZH vs HUMA Comparison
ZH vs HUMA Comparison
Compare ZH & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZH
- HUMA
- Stock Information
- Founded
- ZH 2011
- HUMA 2004
- Country
- ZH China
- HUMA United States
- Employees
- ZH N/A
- HUMA N/A
- Industry
- ZH Business Services
- HUMA Biotechnology: Pharmaceutical Preparations
- Sector
- ZH Consumer Discretionary
- HUMA Health Care
- Exchange
- ZH Nasdaq
- HUMA Nasdaq
- Market Cap
- ZH 365.1M
- HUMA 250.2M
- IPO Year
- ZH 2021
- HUMA N/A
- Fundamental
- Price
- ZH $4.81
- HUMA $1.51
- Analyst Decision
- ZH Strong Buy
- HUMA Strong Buy
- Analyst Count
- ZH 1
- HUMA 8
- Target Price
- ZH $4.70
- HUMA $10.88
- AVG Volume (30 Days)
- ZH 390.5K
- HUMA 5.9M
- Earning Date
- ZH 08-27-2025
- HUMA 08-11-2025
- Dividend Yield
- ZH N/A
- HUMA N/A
- EPS Growth
- ZH N/A
- HUMA N/A
- EPS
- ZH 0.22
- HUMA N/A
- Revenue
- ZH $439,821,184.00
- HUMA $818,000.00
- Revenue This Year
- ZH N/A
- HUMA N/A
- Revenue Next Year
- ZH $7.46
- HUMA $949.92
- P/E Ratio
- ZH $21.62
- HUMA N/A
- Revenue Growth
- ZH N/A
- HUMA N/A
- 52 Week Low
- ZH $3.13
- HUMA $1.15
- 52 Week High
- ZH $6.32
- HUMA $6.77
- Technical
- Relative Strength Index (RSI)
- ZH 56.37
- HUMA 36.87
- Support Level
- ZH $4.58
- HUMA $1.43
- Resistance Level
- ZH $5.01
- HUMA $1.67
- Average True Range (ATR)
- ZH 0.28
- HUMA 0.15
- MACD
- ZH 0.02
- HUMA -0.01
- Stochastic Oscillator
- ZH 55.91
- HUMA 23.32
About ZH Zhihu Inc. (every two of each representing one ordinary share)
Zhihu Inc is predominantly engaged in the operation of one online content community and monetizes through paid membership services, advertising services, content-commerce solutions services, and vocational training in China. It generates revenues from Advertising services, Paid membership services, Content-commerce solutions, and Others. It derives all its revenues within China.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.